IMPROVING THE LIVES OF PATIENTS SUFFERING FROM INFLAMMATORY DISEASES

Katexco has shown in animal models that their patented molecules engage key receptors on immune cells that reduced inflammatory diseases.

PRIMARY TARGET INDICATIONS

GASTROINTESTINAL
DISORDERS
GOUT
MULTIPLE SCLEROSIS BOTH
RELAPSING AND PROGRESSIVE FORMS

SECONDARY TARGET INDICATIONS

RHEUMATOID
ARTHRITIS
OSTEOARTHRITIS
ATHEROSCLEROSIS

A HIGHLY EXPERIENCED TEAM

Katexco Co-Founders Prof Lawrence Steinman, Dr Jonathan Rothbard and Prof Sir Marc Feldmann are industry leading scientists who are experts in the development of anti-inflammatory therapeutics and are at the forefront of Katexco mission to develop safe medicines for patients most in need.

THE BENEFITS OF MEDICAL MARIJUANA PHARMA ARE BEING REALIZED GLOBALLY

The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Marijuana has shown its benefits in multiple suppressive and therapeutic indications.

Source: FULD+Company Analyst Report, Market and Competitive landscape for Medical Marijuana and synthetic cannabi-noids